Endovastec(SH:688016) Xin Lang Cai Jing·2025-10-30 06:26Core Points - On October 30, Xinmai Medical experienced a decline of 5.03%, trading at 100.12 CNY per share, with a transaction volume of 375 million CNY and a turnover rate of 3.00%, resulting in a total market capitalization of 12.341 billion CNY [1] Company Overview - Shanghai MicroPort CardioFlow Medtech Co., Ltd. was established on August 17, 2012, and went public on July 22, 2019. The company specializes in the research, development, production, and sales of interventional medical devices for aortic and peripheral blood vessels [1] - The revenue composition of the company is as follows: 71.94% from aortic products, 28.04% from peripheral and other products, and 0.02% from other supplementary sources [1] Shareholder Information - Among the top ten circulating shareholders of Xinmai Medical, a fund under Huabao Fund holds a significant position. The Huabao CSI Medical ETF (512170) reduced its holdings by 301,200 shares in the third quarter, now holding 2.115 million shares, which accounts for 1.72% of the circulating shares [2] - The Huabao CSI Medical ETF (512170) was established on May 20, 2019, with a latest scale of 26.404 billion CNY. Year-to-date, it has achieved a return of 15%, ranking 3359 out of 4216 in its category; over the past year, it has returned 8.02%, ranking 3532 out of 3885; and since inception, it has returned 12.69% [2] - The fund manager of Huabao CSI Medical ETF is Hu Jie, who has a tenure of 13 years and 18 days, managing total assets of 100.204 billion CNY. During his tenure, the best fund return was 180.89%, while the worst was -98.01% [2]